ArticleCurrent treatment options in psychiatry2015
Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.
Article in Current treatment options in psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial.Schizophrenia bulletin · 2021Trial
- Effective factors in the pathogenesis ofHeliyon · 2024Review
- Iowa Gambling Task performance in individuals with schizophrenia: the role of general versus specific cognitive abilities.Frontiers in psychiatry · 2024Article
- Mismatch Negativity (MMN) as a Pharmacodynamic/Response Biomarker for NMDA Receptor and Excitatory/Inhibitory Imbalance-Targeted Treatments in Schizophrenia.Advances in neurobiology · 2024Review
- Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- Toxoplasmosis: Targeting neurotransmitter systems in psychiatric disorders.Metabolic brain disease · 2022Review
- Persistent negative symptoms in individuals at Ultra High Risk for psychosis.Schizophrenia research · 2019Article
- Rodent Mismatch Negativity/theta Neuro-Oscillatory Response as a Translational Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New Treatment Development in Schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Article
- Septal Cholinergic Neuromodulation Tunes the Astrocyte-Dependent Gating of Hippocampal NMDA Receptors to Wakefulness.Neuron · 2017Article
- The current conceptualization of negative symptoms in schizophrenia.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2017Article
- Modulating NMDA Receptor Function with D-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model.Neurochemical research · 2016Article
- Time to Re-focus onto Cognitive Symptoms in Schizophrenia.Indian journal of psychological medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.